JETEMA Co., Ltd. is a Korean aesthetic biopharmaceutical company headquartered in Wonju, South Korea. Founded in 2009 and listed on the KOSDAQ market, the company develops and manufactures botulinum toxin, hyaluronic acid fillers, PDO threads, and skinbooster products for medical aesthetic practices.
The company operates its own manufacturing facilities in Wonju and Yongin under cGMP and ISO 13485 quality systems. Its hyaluronic acid filler line, e.p.t.q.®, carries CE marking and Korean MFDS approval, and JETEMA products are supplied to markets across Europe, Asia, and Latin America. JETEMA established its U.S. subsidiary, Jetema USA Inc., in Irvine, California, which began operations in December 2024.
JETEMA THE TOXIN® Inj. is the company’s botulinum toxin type A product, supplied as a purified neurotoxin complex in 100-unit vials for intramuscular use. In July 2026, it received marketing approval from the Thai FDA, the company’s first overseas approval for a botulinum toxin product.
Named after the Latin "Zetéma," meaning research.
Toxin, fillers, threads, and skinboosters in a single portfolio.
cGMP and ISO 13485 manufacturing; CE-marked filler line.
Supplied across Europe, Asia, and Latin America, with a U.S. subsidiary.
